On April 12, 2023, Weiss Asset Management LP announced that it has had and anticipate having further discussions with the directors of Theravance Biopharma Inc, in connection with its investment in the Company. In addition, Weiss Asset Management stated that the topics of these conversations may cover a range of issues, including those relating to the business of the Company, management, board composition, investor communications, operations, capital allocation, dividend policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation, and corporate governance.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.925 USD | -1.92% | -4.90% | -20.55% |
May. 13 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
May. 13 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.55% | 443M | |
+37.87% | 705B | |
+32.82% | 583B | |
-3.66% | 364B | |
+20.21% | 332B | |
+4.95% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.73% | 169B |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Weiss Asset Management Engages with Theravance Biopharma